DE69432626D1 - Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen - Google Patents

Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen

Info

Publication number
DE69432626D1
DE69432626D1 DE69432626T DE69432626T DE69432626D1 DE 69432626 D1 DE69432626 D1 DE 69432626D1 DE 69432626 T DE69432626 T DE 69432626T DE 69432626 T DE69432626 T DE 69432626T DE 69432626 D1 DE69432626 D1 DE 69432626D1
Authority
DE
Germany
Prior art keywords
treatment
melatonin derivatives
desynchronization disorders
disorders
desynchronization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432626T
Other languages
English (en)
Other versions
DE69432626T2 (de
Inventor
Michael Edward Flaugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69432626D1 publication Critical patent/DE69432626D1/de
Publication of DE69432626T2 publication Critical patent/DE69432626T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69432626T 1993-11-18 1994-11-16 Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen Expired - Fee Related DE69432626T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US154903 1993-11-18
US08/154,903 US6180657B1 (en) 1993-11-18 1993-11-18 Melatonin derivatives for use in treating desynchronization disorders

Publications (2)

Publication Number Publication Date
DE69432626D1 true DE69432626D1 (de) 2003-06-12
DE69432626T2 DE69432626T2 (de) 2004-04-08

Family

ID=22553300

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432626T Expired - Fee Related DE69432626T2 (de) 1993-11-18 1994-11-16 Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen

Country Status (21)

Country Link
US (1) US6180657B1 (de)
EP (1) EP0656209B1 (de)
JP (1) JPH07196504A (de)
KR (1) KR950013509A (de)
CN (1) CN1100533C (de)
AT (1) ATE239470T1 (de)
AU (1) AU7777694A (de)
CA (1) CA2135710C (de)
CZ (1) CZ288834B6 (de)
DE (1) DE69432626T2 (de)
DK (1) DK0656209T3 (de)
ES (1) ES2197904T3 (de)
HU (1) HUT72070A (de)
IL (1) IL111579A (de)
NO (1) NO307364B1 (de)
NZ (1) NZ264893A (de)
PT (1) PT656209E (de)
RU (1) RU2160101C2 (de)
SG (1) SG77569A1 (de)
UA (1) UA35588C2 (de)
ZA (1) ZA948928B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748627A3 (de) * 1995-06-14 1997-05-21 Lilly Co Eli Melatoninagonisten zur Behandlung von gutartigen Hyperplasieformen der Prostata
WO2005062992A2 (en) * 2003-12-23 2005-07-14 Abraxis Bioscience, Inc Substituted melatonin derivatives, process for their preparation, and methods of use
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
WO2009140754A1 (en) * 2008-05-19 2009-11-26 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102317399B1 (ko) 2012-01-26 2021-10-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
CN105142630A (zh) 2012-12-18 2015-12-09 万达制药公司 昼夜节律紊乱的治疗
RU2533965C1 (ru) * 2013-07-04 2014-11-27 Государственное бюджетное учреждение здравоохранения "Самарский областной гериатрический центр" Способ нормализации циркадианных ритмов человека
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
RU2655813C1 (ru) * 2017-06-09 2018-05-29 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Средство коррекции и профилактики состояний, вызванных нарушением суточных ритмов

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087444A (en) 1976-09-08 1978-05-02 Eli Lilly And Company Amides as ovulation inhibitors
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US4614807A (en) 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
US4687763A (en) 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
EP0375726A4 (en) 1987-08-17 1991-01-30 Whitby Research Incorporated Melatonin analogues
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
CA2116036A1 (en) * 1991-10-18 1993-04-29 F. Eugene Yates Device for the transdermal administration of melatonin
US5196435A (en) 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin

Also Published As

Publication number Publication date
SG77569A1 (en) 2001-01-16
NO307364B1 (no) 2000-03-27
CZ288834B6 (cs) 2001-09-12
HUT72070A (en) 1996-03-28
CN1107700A (zh) 1995-09-06
CN1100533C (zh) 2003-02-05
AU7777694A (en) 1995-05-25
IL111579A0 (en) 1995-01-24
DK0656209T3 (da) 2003-09-01
IL111579A (en) 1999-10-28
ZA948928B (en) 1996-05-10
NO944340D0 (no) 1994-11-14
US6180657B1 (en) 2001-01-30
HU9403299D0 (en) 1995-01-30
RU2160101C2 (ru) 2000-12-10
EP0656209B1 (de) 2003-05-07
NO944340L (no) 1995-05-19
RU94041028A (ru) 1996-09-20
PT656209E (pt) 2003-09-30
KR950013509A (ko) 1995-06-15
NZ264893A (en) 1997-06-24
ATE239470T1 (de) 2003-05-15
UA35588C2 (uk) 2001-04-16
CA2135710A1 (en) 1995-05-19
CA2135710C (en) 2007-07-10
ES2197904T3 (es) 2004-01-16
DE69432626T2 (de) 2004-04-08
JPH07196504A (ja) 1995-08-01
EP0656209A3 (de) 1995-10-11
EP0656209A2 (de) 1995-06-07
CZ276494A3 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69307509D1 (de) Vorrichtung zur behandlung von herzfehlern
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
DE59209268D1 (de) Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
ATE187442T1 (de) Tryptamine zur behandlung von störungen der circadianen rhythmik
DE69314413D1 (de) Piperidino-3,4-dihydrocarbostyryl Verbindungen zur Behandlung von ischämischen Störungen
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee